Bharat Parenterals schedules 33rd AGM for September 19

scanx
Reviewed by
Riya DScanX News Team
Key Highlights

Bharat Parenterals schedules its 33rd AGM for September 19, 2026. The meeting will be held via video conference starting at 11:00 am. September 12, 2026 is set as the record date for final dividend eligibility. NSDL will provide the platform for remote e-voting and meeting access. Shareholders must register email addresses to receive AGM documents electronically.

powered bylight_fuzz_icon
49106591

*this image is generated using AI for illustrative purposes only.

Bharat Parenterals Limited has scheduled its 33rd Annual General Meeting (AGM) for September 19, 2026. The meeting will commence at 11:00 am and will be conducted through Video Conferencing or Other Audio-Visual Means, in compliance with applicable regulatory circulars.

Meeting Details and Logistics

The company announced that the AGM will be held without the physical presence of members at a common venue. Shareholders can attend the proceedings via an electronic platform. The notice of the AGM, along with the Annual Report for FY25-26, will be dispatched electronically to members who have registered their email addresses with the company or their Depository Participants.

Members holding shares in physical form or those who have not registered their email addresses are advised to update their details to receive the documents and login credentials for e-voting. The company has engaged NSDL as the authorized agency to facilitate remote e-voting and voting during the meeting.

Record Date and Dividend Eligibility

Bharat Parenterals has fixed September 12, 2026, as the record date for determining shareholder eligibility for the payment of the final dividend for FY25-26, subject to approval at the AGM. Investors are urged to ensure their KYC details, including PAN and bank account information, are updated to avoid any issues with dividend processing or folio freezing.

E-Voting Process

Pursuant to Section 108 of the Companies Act, 2013, and SEBI Listing Regulations, members will have the opportunity to cast their votes using remote e-voting or the e-voting system available during the AGM. Detailed instructions for joining the meeting and casting votes will be provided in the official notice of the AGM.

Historical Stock Returns for Bharat Parenterals

1 Day5 Days1 Month6 Months1 Year5 Years
+3.16%+10.27%+10.27%+10.27%+10.27%+10.27%

What is the expected dividend payout ratio for FY25-26, and how does it compare to the company's historical distribution trends?

How might the shift to a fully virtual AGM impact shareholder engagement and voting participation rates for Bharat Parenterals?

Are there any significant capital expenditure or strategic expansion plans outlined in the FY25-26 Annual Report that could influence future growth?

Bharat Parenterals equity shares begin trading on NSE

scanx
Reviewed by
Riya DScanX News Team
Key Highlights

Bharat Parenterals Limited shares began trading on the NSE on August 17, 2026, under the symbol BPLPHARMA. The listing adds to the company's existing presence on the BSE. The move follows regulatory approval under SEBI LODR Regulations.

powered bylight_fuzz_icon
48756060

*this image is generated using AI for illustrative purposes only.

Bharat Parenterals Limited equity shares have been permitted to trade and admitted to dealings on the National Stock Exchange of India Limited (NSE). The trading commenced on August 17, 2026, under the Permitted to Trade category in the Capital Market Segment.

The company disclosed the development pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was issued on August 20, 2026, by Sharmin Nareshkumar Soni, Company Secretary & Compliance Officer.

Listing Details

The NSE notified its members of the admission via Circular No. NSE/CML/75748 dated August 14, 2026. The circular specified the security codes and lot sizes for trading purposes.

Parameter Detail
Symbol BPLPHARMA
Series EQ
Face Value ₹10
No. of Securities 6,891,963
Market Lot 1

Regulatory Context

The admission aligns with Regulation 3.1.1 of the National Stock Exchange (Capital Market) Trading Regulations Part A. Trading in the securities is identified by the designated code BPLPHARMA. The market lot size for the securities is fixed at 1.

Bharat Parenterals Limited was already listed on the Bombay Stock Exchange. The NSE listing adds a secondary exchange platform for its equity shares. The company operates from Vadodara, Gujarat, and holds WHO-GMP certification.

Historical Stock Returns for Bharat Parenterals

1 Day5 Days1 Month6 Months1 Year5 Years
+3.16%+10.27%+10.27%+10.27%+10.27%+10.27%

How might the dual listing on NSE impact the liquidity and trading volume of Bharat Parenterals Limited shares compared to its BSE performance?

What are the immediate short-term price discovery expectations for BPLPHARMA given its admission under the 'Permitted to Trade' category?

Could the expanded investor base from the NSE listing accelerate Bharat Parenterals' capital raising plans for future expansion or R&D in parenteral products?

More News on Bharat Parenterals

1 Year Returns:+10.27%